🇺🇸

Regulatory Compliance

US SEC Filing Intelligence · 148 digests

· daily

US SEC Trading Suspension Halt Orders — October 16, 2026

Across the nine filings in the USA Trading Suspensions stream, the dominant theme is Nasdaq and NYSE listing-compliance stress rather than outright trading halts: five companies (eHealth, Lucid Diagnostics, Health In Tech, Bridgeline Digital, Canopy Growth) received $1.00 minimum bid price deficiency notices, all with an April 12, 2027 compliance deadline, and Callan JMB faces a hard suspension date of October 21, 2026 absent a successful hearing. A second cluster is voluntary or sponsor-driven delisting: SITE Centers (Form 25 targeted November 23, 2026, trading ends before December 4) and Apollo Commercial Real Estate Finance (Form 25 around October 27, last NYSE trade November 6, no stated reason). Aether Holdings carries a governance deficiency (missed annual meeting) with a November 27, 2026 compliance-plan deadline. The filings contain little quantitative period-over-period financial data, so the signal is largely event-driven: the most time-critical items are Callan JMB's October 19 appeal deadline and October 21 suspension date, Canopy Growth's October 23 reconvened reverse-split vote, and the November wave of NYSE/Form 25 dates. Market implication: the reverse-split/bid-price cohort faces dilution and potential delisting risk, while the voluntary delistings are more event-driven and less indicative of distress.

9 high priority 9 total filings
· daily

US SEC Trading Suspension Halt Orders — October 15, 2026

This digest covers two Nasdaq minimum bid price deficiency notices, both issued in October 2026 to small-cap companies whose common stock has closed below $1.00 for 30 consecutive business days. Innovative Eyewear (LUCY) received its notice on October 9, 2026 with a compliance deadline of April 7, 2027, while Cyngn (CYN) received its notice on October 14, 2026 with a deadline of April 12, 2027. Both notices are formally non-disruptive to listing status today, but both companies face a 180-day window to regain compliance by closing at or above $1.00 for 10 consecutive business days. The filings provide no period-over-period financial comparisons, insider transaction data, capital allocation details, or quantified forward guidance, so the enriched-data signals available for quantitative analysis are limited. The common theme is that both companies are exposed to potential reverse stock split actions and, if they fail to cure, to delisting proceedings with a right to a Nasdaq Hearings Panel review. The sector read-across is that sub-$1 equity is a shared pressure point for these issuers, with event risk clustered in the first half of 2027.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — October 14, 2026

Both filings in this window concern Nasdaq listing-compliance matters rather than SEC trading suspensions per se, but they fall within the stream's Delisting and Regulatory Halt scope. AMASS Brands received a Nasdaq notice on October 9, 2026 for 30 consecutive business days below $1.00 (Rule 5450(a)(1)), with a compliance deadline of April 7, 2027, and it also carries a separate market value deficiency with a January 19, 2027 deadline. Netcapital Inc. regained bid-price compliance on October 7, 2026 after 10 consecutive business days at or above $1.00, but remains non-compliant with Rule 5250(c)(1) for late FY2026 10-K and Q1 FY2027 10-Q filings, with a compliance plan due October 23, 2026. The Netcapital situation is the more severe governance story: its FY2022 through FY2025 financial statements were declared unreliable, its prior auditor resigned, and a re-audit of FY2022 through FY2026 is underway. Enriched period-over-period, insider, forward-looking, and capital-allocation fields were not populated for either filing, so quantitative trend analysis is not possible from this data. The dominant theme is that sub-$1 price and filing-delinquency issues are colliding, creating delisting pathways that investors should track against specific dates.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — October 13, 2026

All four filings in this trading-suspension, delisting, and regulatory-halt stream are Nasdaq or NYSE listing-compliance actions dated around October 6-8, 2026, and every one falls squarely within scope. Two filings (ClearOne and Newton Golf) involve stockholders' equity deficiencies under Nasdaq Rule 5550(b)(1) with imminent suspension or delisting dates (October 15 and October 19, 2026), while Equus faces a sub-$1.00 price deficiency on the NYSE and CN Healthy Food Tech has received a Panel decision permitting continued listing under a one-year monitor. The filings provide no period-over-period financial metrics, guidance, insider transactions, or capital allocation data, so quantitative trend analysis is not possible from this set; the signals below rest on event timing and regulatory status. The dominant theme is that a fundamental capital/equity shortfall is driving the most acute delisting risk, with the two Nasdaq equity-deficiency cases carrying the highest materiality and nearest deadlines. Investors should treat the October 13-20 window as the critical catalyst period for this group.

4 high priority 4 total filings
· daily

US SEC Trading Suspension Halt Orders — October 09, 2026

All five filings in this stream are negative-sentiment regulatory notices concerning US listing compliance rather than trading halts themselves: four involve Nasdaq or NYSE/NYSE American deficiency or delisting notices (minimum bid price, stockholders' equity, board governance, and late SEC filings), and none of the five has an immediate suspension in effect. The dominant theme is sub-$1.00 price and equity-deficiency pressure in small-cap issuers, with two companies (Streamex and Accendra Health) facing bid-price deadlines and one (Alaunos) facing an active delisting process that is stayed pending a Hearings Panel. Governance breakdown (Better Home & Finance) and reporting failure (IT Tech Packaging) show that non-price compliance failures are also driving exchange actions. The enriched fields for period-over-period financials, insider activity, forward-looking guidance, and capital allocation are largely absent from these notices, so the analysis rests on the regulatory timelines and deadlines disclosed. Market implication: the clearest near-term risk events are the Alaunos hearing and the Better Home compliance-plan deadline, while the longer-dated deadlines (April 2027) mainly signal potential reverse splits and dilution.

5 high priority 5 total filings
· daily

US SEC Trading Suspension Halt Orders — October 06, 2026

The USA Trading Suspensions stream for October 6, 2026, is dominated by three distinct Nasdaq listing actions, reflecting a bifurcated market: two companies (FibroGen/Kyntra Bio and Virtuix) face involuntary delisting due to failure to meet continued listing standards, while one (International Bancshares) voluntarily departs for a regional exchange. The involuntary delistings highlight a trend of small-cap distress, with both companies failing the $50M total assets/revenue alternative standard, and both are pursuing hearings or compliance periods to maintain their listings. Sentiment is negative for the two distressed companies (materiality 9/10 and 8/10), while the voluntary transfer is neutral (materiality 5/10), indicating no financial distress. Key forward-looking catalysts include Nasdaq Hearings Panel decisions (FibroGen) and a compliance deadline of March 29, 2027 (Virtuix), while IBOC's TXSE listing begins October 19, 2026. No insider trading or capital allocation data was provided in the enriched filings, limiting insights in those areas. The pattern suggests a regulatory environment where Nasdaq is actively enforcing listing standards, potentially creating trading opportunities in distressed securities and a shift toward alternative exchanges.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — October 05, 2026

This digest covers three US trading suspension events on October 5, 2026, revealing a bifurcated market: two companies face involuntary delisting due to market capitalization failures, while one voluntarily migrates to a new exchange. ESS Tech (GWH) received a second NYSE delisting notice after failing to maintain a $15 million average market cap over 30 days, with trading suspended immediately—a severe bearish signal amplified by the lack of insider buying or capital allocation actions. Purple Innovation (PRPL) received a Nasdaq non-compliance notice for the same $15 million threshold, with a 180-day cure period, but no insider activity or financial data suggests a credible turnaround. CECO Environmental (CECO) voluntarily delisted from Nasdaq to join the Texas Stock Exchange (TXSE), a neutral strategic move that preserves liquidity. No period-over-period comparisons, insider transactions, forward-looking guidance, or capital allocation data were provided in any filing, limiting quantitative trend analysis. The key takeaway: micro-cap and distressed companies face heightened delisting risk under NYSE/Nasdaq minimum market cap rules, while exchange migration offers an alternative for firms seeking lower regulatory costs.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — October 02, 2026

This digest covers 8 regulatory filings from October 2, 2026, all involving trading suspensions or delistings on US exchanges (NYSE American and Nasdaq). The dominant theme is a wave of micro-cap and pre-revenue companies failing to maintain minimum bid price or market value standards, with 6 of 8 filings triggered by sub-$1.00 bid prices. Notably, Healthcare Triangle faces an expedited delisting due to two reverse stock splits in two years, while Direct Digital Holdings and Amaze Holdings have already received final delisting notices with no appeal. The cluster of filings on September 28-29, 2026, suggests a coordinated exchange compliance review. No period-over-period financial data, insider activity, or capital allocation metrics were available in these filings, limiting quantitative trend analysis. The materiality is uniformly high (8-10/10), as delisting from a major exchange to OTC Pink or similar severely impairs liquidity and capital access. The key forward-looking dates cluster around March 29, 2027, for compliance deadlines, creating a catalyst calendar for investors to monitor.

8 high priority 8 total filings
· daily

US SEC Trading Suspension Halt Orders — October 01, 2026

The October 1, 2026 filings show a concentrated listing-status theme: one completed merger and Nasdaq delisting, one voluntary exchange transfer, two Nasdaq compliance notices, one NYSE suspension and OTC migration, and one board-composition deficiency. The most severe developments are Getty Images' immediate NYSE suspension and Lantern Pharma's failure to satisfy the $35 million minimum market value of listed securities requirement. Gaxos.ai faces a sub-$1.00 bid-price deficiency, while SKYX Platforms must rebuild its independent-board and audit-committee composition after the death of a director. NSTS Bancorp represents a completed liquidity event, with shareholders receiving $14.31 per share in cash and approximately $73.7 million in aggregate consideration. Nextdoor's move from NYSE to Nasdaq is operationally neutral but creates a defined October 14, 2026 trading catalyst. No filing supplied revenue, margin, earnings guidance, insider-trading, dividend, buyback, or valuation-comparison data; therefore, the actionable conclusions are driven primarily by regulatory status, cure periods, transaction terms, and trading-liquidity risk rather than operating-performance trends.

6 high priority 6 total filings
· daily

US SEC Trading Suspension Halt Orders — September 30, 2026

The two filings in this digest both involve US-listed companies facing imminent delisting actions from their primary exchanges, signaling a period of heightened regulatory and financial distress in the small/micro-cap biotech and clean-tech sectors. ESS Tech received a NYSE notice on September 24, 2026, for failing to meet the $50M stockholders' equity or market cap standard, while Outlook Therapeutics received a Nasdaq deficiency notice on September 25, 2026, for its sub-$1.00 bid price over 30 consecutive days. Both companies face negative sentiment and high materiality (9/10 and 8/10 respectively), with appeals and cure periods offering only uncertain paths to survival. The concentration of these events within a 24-hour window suggests a broader trend of exchange enforcement tightening on financially distressed issuers, potentially signaling a wave of delistings in the micro-cap space. Investors should monitor the appeal timelines and compliance deadlines closely, as failure to cure will lead to trading suspensions and potential OTCQB/OTCQX downgrades, impacting liquidity and valuation.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — September 29, 2026

The four filings in this digest highlight a significant wave of regulatory and structural stress across US-listed companies, with three of four facing Nasdaq delisting risks and one completing a going-private transaction. Notably, all three Nasdaq-related filings involve compliance failures (delinquent filings, bid price deficiencies), suggesting a pattern of small-cap distress. SurgePays and Liminatus Pharma have received extensions or regained compliance, but both face ongoing financial challenges, with SurgePays' future hinging on a potential reverse split. Maison Solutions' delinquency is the most severe, with a tight timeline to submit a compliance plan. In contrast, Global Business Travel Group's $6.3 billion acquisition by Long Lake Management represents a successful exit, with stockholders receiving a 65.1% premium. The overall sentiment is predominantly negative, with only the GBT deal offering a positive outcome, reflecting a bifurcated market where distressed small caps struggle while larger entities find strategic exits.

4 high priority 4 total filings
· daily

US SEC Trading Suspension Halt Orders — September 28, 2026

The two filings in this digest highlight a critical regulatory theme: small-cap companies are facing intense Nasdaq listing compliance pressure, with both Hain Celestial Group and Nexalin Technology receiving extensions but remaining under significant delisting risk. Hain Celestial's transfer to the Nasdaq Capital Market and extended 180-day compliance period through March 22, 2027, comes alongside the resignation of its Chief Accounting Officer, creating a dual overhang of governance and listing uncertainty. Nexalin Technology faces a more acute situation with a September 28, 2026 deadline to demonstrate a $1.00 closing bid price for 20 consecutive sessions, and a January 4, 2027 deadline to meet the $2.5M stockholders' equity requirement, with the company already ineligible for further extensions. Both companies exhibit negative sentiment and high materiality, with Nexalin at 9/10 and Hain at 8/10, indicating elevated risk of adverse outcomes. The concentration of these events on the same day (September 28, 2026) suggests a potential sector-wide pattern of micro-cap distress, possibly driven by broader market volatility or sector-specific headwinds. Investors should monitor these situations closely, as failure to meet conditions will likely result in immediate trading suspensions or delistings, creating significant downside risk for current shareholders.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — September 25, 2026

This intelligence stream reveals a concentrated wave of trading suspensions and delisting threats across US exchanges, primarily Nasdaq and NYSE, with 9 of 10 filings representing newly published distress signals. The dominant theme is the failure to maintain minimum market capitalization and bid price requirements, with 5 companies (Silexion, Dyadic, SANUWAVE, Fusemachines, SilverBox Corp IV) facing delisting for breaching these thresholds. A secondary cluster involves financial reporting non-compliance (Netcapital) and sustained net losses eroding stockholders' equity (Southland Holdings, Calidi Biotherapeutics). Notably, two companies—Paramount Skydance Corp and Lumen Technologies—are voluntarily transferring listings to NYSE and Nasdaq, respectively, signaling strategic repositioning rather than distress. The aggregate picture shows a tightening regulatory environment where small-cap and micro-cap companies are particularly vulnerable, with compliance deadlines clustering between October 2026 and March 2028. Insider trading data and forward-looking statements are sparse across these filings, but the absence of insider buying in the face of existential delisting risk is itself a bearish signal. The most critical development is SilverBox Corp IV's immediate trading suspension and forced migration to OTC, representing a total loss of exchange liquidity for its shareholders.

10 high priority 10 total filings
· daily

US SEC Trading Suspension Halt Orders — September 24, 2026

The single filing in this digest for the USA Trading Suspensions stream relates to Beasley Broadcast Group Inc., which disclosed a governance non-compliance event following the passing of independent director Peter A. Bordes, Jr. This event reduced the Audit Committee to two members, triggering a violation of Nasdaq Rule 5605(c)(2)(A) which requires a minimum of three independent audit committee members. While not a financial performance event, this governance lapse carries a materiality score of 6/10 and a negative sentiment, as it introduces regulatory risk and potential reputational damage. The company has a cure period until the earlier of its next annual meeting or September 19, 2027, to restore compliance, providing a long runway but creating a monitoring situation. No period-over-period comparisons, insider activity, forward-looking guidance, or capital allocation data were available in the enriched data to derive broader trends. The key theme is a single-company governance risk event with a defined remediation timeline, which could lead to a trading suspension or delisting if not resolved, though the risk is currently low given the extended cure period.

1 high priority 1 total filings
· daily

US SEC Trading Suspension Halt Orders — September 23, 2026

This intelligence digest covers two Nasdaq-listed micro-cap companies, SCWorx Corp. (WORX) and Aditxt, Inc. (ADTX), both of which received regulatory suspensions and face imminent delisting. The filings reveal a common theme: structural non-compliance with exchange listing rules—specifically the publicly held shares requirement for WORX and broader deficiencies for ADTX—leading to trading suspensions and subsequent transfers to the OTC markets. SCWorx has temporarily staved off delisting via a private placement that cures the share deficiency, and is actively petitioning the Panel for reconsideration, creating a binary catalyst around its October 5, 2026, deadline to also meet the bid price rule. In contrast, Aditxt's path to the OTC is terminal, with Nasdaq having formally filed a Form 25 for removal. From an aggregate perspective, both companies exhibit severe financial distress: no revenue growth or margin trends are reported, insider trading activity is absent, and no capital allocation actions (dividends/buybacks) are occurring. The portfolio-level implication is a heightened risk for investors exposed to distressed micro-caps reliant on reverse splits and dilutive placements to maintain listings, as regulatory scrutiny and time pressures intensify.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — September 22, 2026

Reborn Coffee, Inc. (REBN) faces a critical Nasdaq delisting risk after reporting only $735,642 in stockholders' equity against the $2.5M minimum requirement—a shortfall of $1.76M (70% below the threshold). The company has until November 2, 2026, to submit a compliance plan, but does not currently meet alternative standards based on market value or net income, making the path to compliance uncertain. While a prior filing delinquency was resolved on September 14, 2026, the equity deficiency is a material going-concern risk that could lead to a trading suspension or delisting. The negative sentiment and high materiality (9/10) underscore the urgency for investors to monitor the company's next steps. No period-over-period financial trends, insider activity, or capital allocation data were provided, limiting broader trend analysis. The single filing highlights a regulatory event with immediate implications for REBN's listing status and investor positioning.

1 high priority 1 total filings
· daily

US SEC Trading Suspension Halt Orders — September 21, 2026

Linkhome Holdings Inc. (LHAI) successfully resolved its Nasdaq delisting risk by regaining compliance with the Minimum Bid Price Requirement, confirmed via an 8-K filing on September 18, 2026. The stock maintained a closing bid price above $1.00 for 10 consecutive business days (September 3–17, 2026), reversing the non-compliance notice received on June 29, 2026. This positive development removes an immediate overhang, though the company remains subject to ongoing Nasdaq listing standards. The resolution highlights the volatility and regulatory scrutiny typical of micro-cap stocks on the Nasdaq Capital Market. No other filings in this stream provide period-over-period comparisons, insider activity, forward-looking guidance, or capital allocation data, limiting the breadth of cross-company analysis.

1 high priority 1 total filings
· daily

US SEC Trading Suspension Halt Orders — September 18, 2026

The September 18, 2026, trading suspension stream is dominated by a severe and concentrated wave of Nasdaq deficiency notices, with 8 out of 9 filings (89%) involving companies at immediate risk of delisting, primarily due to failure to maintain the minimum $1.00 bid price. This cluster reveals a systemic liquidity crisis among micro-cap and pre-revenue biotech firms, with companies like Moleculin Biotech and NEXTNRG facing an expedited path to delisting due to ineligibility for standard cure periods, having exhausted their reverse-split options. The lone outlier is Dillard's voluntary, strategic transfer from NYSE to the Texas Stock Exchange (TXSE), a non-distressed delisting driven by corporate governance preference rather than financial failure. Critically, no new insider buying was detected across these distressed firms, signaling a profound lack of management confidence in their own recovery, while InMed Pharmaceuticals presents a unique shareholders' equity deficiency tied to a transformative merger, offering a potential (but risky) catalyst to avoid delisting. The aggregate data paints a picture of a harsh capital market environment for low-priced equities, where penny stock rehabilitation is proving increasingly difficult.

9 high priority 9 total filings
· daily

US SEC Trading Suspension Halt Orders — September 16, 2026

This digest covers 5 regulatory filings related to US trading suspensions and delistings, all published on September 16, 2026. The dominant theme is heightened delisting risk across micro-cap and pre-revenue companies, with 4 out of 5 filings reporting negative compliance events. Synergy CHC Corp. faces an imminent trading suspension on September 18 following its Chapter 11 bankruptcy, representing the most severe event. Aldel Financial II, Bone Biologics, and Exicure are all in various stages of deficiency notices, with forward-looking deadlines creating a catalyst calendar through early 2027. The lone positive signal comes from Battalion Oil Corp, which successfully regained compliance with NYSE American equity standards after two consecutive quarters of improvement, demonstrating that turnaround is possible. No insider trading activity, period-over-period financial comparisons, or capital allocation data were available in these filings, limiting quantitative trend analysis. The sector concentration is heavily weighted toward distressed micro-cap biotechnology and energy companies, suggesting a broader capital market tightening for firms with low market capitalizations and negative earnings.

5 high priority 5 total filings
· daily

US SEC Trading Suspension Halt Orders — September 15, 2026

This digest covers five regulatory filings related to US trading suspensions, delistings, and regulatory halts. The overarching theme is a wave of companies exiting major US exchanges (Nasdaq and NYSE) due to both involuntary and voluntary actions. Three companies face imminent or potential involuntary delisting due to non-compliance with listing standards (SOBR Safe, XMax Inc., InnSuites Hospitality Trust), while two are voluntarily delisting to move to alternative exchanges (zSpace to OTC, Origin Bancorp to the Texas Stock Exchange). The concentration of these events on September 15-16, 2026, suggests a potential end-of-quarter cleanup by exchanges. The most critical development is SOBR Safe's imminent delisting on September 16, which will trigger a severe liquidity event for shareholders. A key portfolio-level pattern is the lack of any positive insider activity or capital allocation actions (buybacks, dividends) across these distressed companies, reinforcing the bearish outlook. The enriched data reveals no period-over-period financial comparisons or forward-looking guidance, as these are event-driven 8-K filings focused on corporate actions rather than operational results.

5 high priority 5 total filings